Ongoing studies are evaluating alternative MDM2 inhibitors in AML, including siremadlin in combination with AZA/VEN (NCT05155709) [126] and the newer MDM2 inhibitor KRT-232 in combination with VEN and DAC (NCT03041688). The gene discussed is MDM2; the disease is acute myeloid leukemia.